Search

Your search keyword '"Baldi, Giacomo Giulio"' showing total 43 results
Start Over Author "Baldi, Giacomo Giulio" Publication Year Range Last 10 years
43 results on '"Baldi, Giacomo Giulio"'

1. Clinical recommendations for treatment of localized angiosarcoma: A consensus paper by the Italian Sarcoma Group

Author

Palassini, Elena, Baldi, Giacomo Giulio, Sulfaro, Sara, Barisella, Marta, Bianchi, Giuseppe, Campanacci, Domenico, Fiore, Marco, Gambarotti, Marco, Gennaro, Massimiliano, Morosi, Carlo, Navarria, Federico, Palmerini, Emanuela, Sangalli, Claudia, Sbaraglia, Marta, Trama, Annalisa, Asaftei, Sebastian, Badalamenti, Giuseppe, Bertulli, Rossella, Bertuzzi, Alexia Francesca, Biagini, Roberto, Buonadonna, Angela, Brunello, Antonella, Callegaro, Dario, Cananzi, Ferdinando, Cianchetti, Marco, Collini, Paola, Comandini, Danila, Curcio, Annalisa, D'Ambrosio, Lorenzo, De Pas, Tommaso, Dei Tos, Angelo Paolo, Ferraresi, Virginia, Ferrari, Andrea, Franchi, Alessandro, Frezza, Anna Maria, Fumagalli, Elena, Ghilli, Matteo, Greto, Daniela, Grignani, Giovanni, Guida, Michele, ibrahim, Toni, Krengli, Marco, Luksch, Roberto, Marrari, Andrea, Mastore, Marinella, Merlini, Alessandra, Milano, Giuseppe Maria, Navarria, Piera, Pantaleo, Maria Abbondanza, Parafioriti, Antonina, Pellegrini, Ilaria, Pennacchioli, Elisabetta, Rastrelli, Marco, Setola, Elisabetta, Tafuto, Salvatore, Turano, Salvatore, Valeri, Sergio, Vincenzi, Bruno, Vitolo, Viviana, Ivanescu, Andrei, Paloschi, Fiammetta, Casali, Paolo Giovanni, Gronchi, Alessandro, and Stacchiotti, Silvia

Published
2024
Full Text
View/download PDF

2. Proximal and Classic Epithelioid Sarcomas are Distinct Molecular Entities Defined by MYC/GATA3 and SOX17/Endothelial Markers, Respectively

Author

Sigalotti, Luca, Frezza, Anna Maria, Sbaraglia, Marta, Del Savio, Elisa, Baldazzi, Davide, Valenti, Beatrice, Bellan, Elena, De Benedictis, Ilaria, Doni, Michele, Gambarotti, Marco, Vincenzi, Bruno, Brunello, Antonella, Baldi, Giacomo Giulio, Palmerini, Emanuela, Pasquali, Sandro, Ciuffetti, Maria Elena, Varano, Veronica, Cappello, Filippo, Appolloni, Viviana, Pastrello, Chiara, Jurisica, Igor, Gronchi, Alessandro, Stacchiotti, Silvia, Casali, Paolo Giovanni, Dei Tos, Angelo Paolo, and Maestro, Roberta

Published
2024
Full Text
View/download PDF

5. The natural history of epithelioid sarcoma. A retrospective multicentre case-series within the Italian Sarcoma Group

Author

Frezza, Anna Maria, Sbaraglia, Marta, Lo Vullo, Salvatore, Baldi, Giacomo Giulio, Simeone, Noemi, Frenos, Filippo, Campanacci, Domenico, Stacchiotti, Silvia, Pasquali, Sandro, Callegaro, Dario, Gambarotti, Marco, Barisella, Marta, Palomba, Annarita, Mariani, Luigi, Casali, Paolo G., Dei Tos, Angelo Paolo, and Gronchi, Alessandro

Published
2020
Full Text
View/download PDF

7. The patient perspective on sirolimus for epithelioid hemangioendothelioma (EHE): results of a community survey highlighting the importance of equitable access to treatments.

Author

Robinson, Denise, Leonard, Hugh, Baldi, Giacomo Giulio, Tap, William D., Jones, Robin L., Stacchiotti, Silvia, and Pantziarka, Pan

Subjects
PATIENTS' attitudes, RAPAMYCIN, DRUG accessibility, DRUG bioavailability, DRUG labeling
Abstract

Background: Epithelioid hemangioendothelioma (EHE) is an ultra-rare, vascular sarcoma with clinical presentation ranging from an indolent to an aggressive form. Over 50% of patients present with metastatic disease, requiring systemic therapy, although no systemic therapies are specifically approved for EHE. Retrospective evidence supports the activity of mTOR inhibitors (e.g. sirolimus), although available only off-label. EHE patients and advocates are therefore working to support approval of effective treatments by collecting data on patient perspectives and experiences. Materials and methods: In February 2023, the EHE Rare Cancer Charity (UK) and The EHE Foundation (US), with other advocates, conducted a survey of perspectives and experiences of EHE patients regarding the use and accessibility of sirolimus. The survey consisted of 20 questions designed for individuals undergoing treatment, those who had been treated, or had never been treated with the drug. Widely promoted within the patient community, the online survey categorized patients into three cohorts for the analysis: liver transplant patients, non-transplant patients who had ever taken sirolimus and sirolimus-naïve non-transplant patients. Results: The survey evaluated data from 129 patient responses from 21 countries, mostly from USA, UK, Australia, and Canada (70%). The liver transplant, sirolimus and non-sirolimus cohorts were 16%, 25% and 59%, respectively. In the sirolimus group 66% reported treatment durations exceeding one year, with 16% exceeding five years, indicating the drug's efficacy. In the non-sirolimus group, the drug was not available for 42% and for 11% sirolimus was available but not selected for treatment because of its off-label status. Overall, 87% of all patients across all cohorts expressed the importance of the drug's availability as hugely or very important. Conclusion: The survey responses highlight the activity of sirolimus for EHE and the importance of securing a label extension for the drug delivering equitable access to this treatment for patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. The rare entity of gastrointestinal leiomyosarcomas: An Italian multicenter retrospective study in high‐volume referral centers

Author

Zagami, Paola, primary, Comandone, Alessandro, additional, Fiore, Marco, additional, Baldi, Giacomo Giulio, additional, Grignani, Giovanni, additional, Vincenzi, Bruno, additional, Gronchi, Alessandro, additional, Antonarelli, Gabriele, additional, Boglione, Antonella, additional, Pennacchioli, Elisabetta, additional, Curigliano, Giuseppe, additional, Conforti, Fabio, additional, and De Pas, Tommaso Martino, additional

Published
2023
Full Text
View/download PDF

11. Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts

Author

Stacchiotti, Silvia, primary, Dürr, Hans Roland, additional, Schaefer, Inga-Marie, additional, Woertler, Klaus, additional, Haas, Rick, additional, Trama, Annalisa, additional, Caraceni, Augusto, additional, Bajpai, Jyoti, additional, Baldi, Giacomo Giulio, additional, Bernthal, Nicholas, additional, Blay, Jean-Yves, additional, Boye, Kjetil, additional, Broto, Javier-Martin, additional, Chen, Wei-Wu Tom, additional, Dei Tos, Paolo Angelo, additional, Desai, Jayesh, additional, Emhofer, Stephan, additional, Eriksson, Mikael, additional, Gronchi, Alessandro, additional, Gelderblom, Hans, additional, Hardes, Jendrik, additional, Hartmann, Wolfgang, additional, Healey, John, additional, Italiano, Antoine, additional, Jones, Robin L., additional, Kawai, Akira, additional, Leithner, Andreas, additional, Loong, Herbert, additional, Mascard, Eric, additional, Morosi, Carlo, additional, Otten, Nadine, additional, Palmerini, Emanuela, additional, Patel, Shreyaskumar R., additional, Reichardt, Peter, additional, Rubin, Brian, additional, Rutkowski, Piotr, additional, Sangalli, Claudia, additional, Schuster, Kathrin, additional, Seddon, Beatrice M., additional, Shkcodra, Morena, additional, Staals, Eric L., additional, Tap, William, additional, van de Rijn, Matt, additional, van Langevelde, Kirsten, additional, Vanhoenacker, Filip M.M., additional, Wagner, Andrew, additional, Wiltink, Lisette, additional, Stern, Sydney, additional, Van de Sande, Michiel, additional, and Bauer, Sebastian, additional

Published
2023
Full Text
View/download PDF

12. Trabectedin in advanced retroperitoneal well differentiated/dedifferentiated liposarcoma and leiomyosarcoma (TRAVELL): Results of a phase 2 study from Italian sarcoma group (ISG).

Author

Sanfilippo, Roberta, primary, Grignani, Giovanni, additional, Fabbroni, Chiara, additional, Vincenzi, Bruno, additional, Fumagalli, Elena, additional, De Pas, Tommaso Martino, additional, Mazzocca, Alessandro, additional, Ibrahim, Toni, additional, Pantaleo, Maria A., additional, Brunello, Antonella, additional, Baldi, Giacomo Giulio, additional, Boglione, Antonella, additional, Fatigoni, Sonia, additional, Marrari, Andrea, additional, Berruti, Alfredo, additional, Giordano, Monica, additional, Dei Tos, Angelo Paolo, additional, Carlucci, Luciano, additional, Rulli, Eliana, additional, and Casali, Paolo Giovanni, additional

Published
2022
Full Text
View/download PDF

13. A Global CollaboRAtive Study of CIC-Rearranged, BCOR::CCNB3-Rearranged and Other Ultra-Rare Unclassified Undifferentiated Round Cell Sarcomas (GRACefUl)

Author

Palmerini, Emanuela, primary, Gambarotti, Marco, additional, Italiano, Antoine, additional, Nathenson, Michael, additional, Ratan, Ravin, additional, Dileo, Palma, additional, Provenzano, Salvatore, additional, Jones, Robin Lewis, additional, DuBois, Steven G., additional, Martin-Broto, Javier, additional, de Alava, Enrique, additional, Baldi, Giacomo Giulio, additional, Grignani, Giovanni, additional, Ferraresi, Virginia, additional, Brunello, Antonella, additional, Paoluzzi, Luca, additional, Bertulli, Rossella, additional, Hindi, Nadia, additional, Montemurro, Michael, additional, Rothermundt, Christian, additional, Cocchi, Stefania, additional, Salguero-Arand, Carmen, additional, Donati, Davide Maria, additional, Diaz Martin, Juan, additional, Abdelhamid Ahmed, Amr, additional, Mazzocca, Alessandro, additional, Carretta, Elisa, additional, Cesari, Marilena, additional, Pierini, Michela, additional, Righi, Alberto, additional, Sbaraglia, Marta, additional, Maria Antonella, Laginestra, additional, Scotlandi, Katia, additional, Dei Tos, Angelo Paolo, additional, Ibrahim, Toni, additional, Stacchiotti, Silvia, additional, and Vincenzi, Bruno, additional

Published
2022
Full Text
View/download PDF

16. Systemic Treatment in Advanced Phyllodes Tumor of the Breast: A Multi-Institutional European Retrospective Case-Series Analyses

Author

Palassini, Elena, primary, Mir, Olivier, additional, Grignani, Giovanni, additional, Vincenzi, Bruno, additional, Gelderblom, Hans, additional, Sebio, Ana, additional, Valverde, Claudia, additional, Baldi, Giacomo Giulio, additional, Brunello, Antonella, additional, Cardellino, Giovanni Gerardo, additional, Marrari, Andrea, additional, Badalamenti, Giuseppe, additional, Martin-Broto, Javier, additional, Ferraresi, Virginia, additional, Libertini, Michela, additional, Turano, Salvatore, additional, Gataa, Ithar, additional, Collini, Paola, additional, Tos, Angelo Paolo Dei, additional, Gennaro, Massimiliano, additional, Bini, Federica, additional, Provenzano, Salvatore, additional, Vullo, Salvatore Lo, additional, Mariani, Luigi, additional, Cesne, Axel Le, additional, and Casali, Paolo Giovanni, additional

Published
2021
Full Text
View/download PDF

18. Magnetic resonance imaging patterns of tumor response to chemotherapy in desmoid‐type fibromatosis

Author

Zanchetta, Edoardo, primary, Ciniselli, Chiara Maura, additional, Bardelli, Annalisa, additional, Colombo, Chiara, additional, Stacchiotti, Silvia, additional, Baldi, Giacomo Giulio, additional, Provenzano, Salvatore, additional, Bertulli, Rossella, additional, Bini, Federica, additional, Casale, Alessandra, additional, Greco, Francesca Gabriella, additional, Ferrari, Andrea, additional, Verderio, Paolo, additional, Fiore, Marco, additional, Gronchi, Alessandro, additional, Casali, Paolo Giovanni, additional, Morosi, Carlo, additional, and Palassini, Elena, additional

Published
2021
Full Text
View/download PDF

19. Regorafenib (R) in advanced solitary fibrous tumor (SFT): Results from an exploratory phase II clinical study.

Author

Stacchiotti, Silvia, primary, Baldi, Giacomo Giulio, additional, Lo Vullo, Salvatore, additional, Morosi, Carlo, additional, Greco, Francesca Gabriella, additional, Collini, Paola, additional, Barisella, Marta, additional, Dagrada, Gianpaolo, additional, Zaffaroni, Nadia, additional, Gronchi, Alessandro, additional, Simeone, Noemi, additional, Mariani, Luigi, additional, Frezza, Anna Maria, additional, and Casali, Paolo Giovanni, additional

Published
2021
Full Text
View/download PDF

20. In Reply

Author

Stacchiotti, Silvia, primary, Baldi, Giacomo Giulio, additional, and Casali, Paolo Giovanni, additional

Published
2020
Full Text
View/download PDF

22. Pharmacokinetics, safety, and activity of trabectedin as first‐line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group

Author

Grosso, Federica, primary, D’Ambrosio, Lorenzo, additional, Zucchetti, Massimo, additional, Ibrahim, Toni, additional, Tamberi, Stefano, additional, Matteo, Cristina, additional, Rulli, Eliana, additional, Comandini, Danila, additional, Palmerini, Emanuela, additional, Baldi, Giacomo Giulio, additional, DeCensi, Andrea, additional, Bergaglio, Marina, additional, Marra, Domenico, additional, Marchesi, Emanuela, additional, Siri, Giacomo, additional, D’Incalci, Maurizio, additional, and Grignani, Giovanni, additional

Published
2020
Full Text
View/download PDF

23. The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis

Author

Baldi, Giacomo Giulio, primary, Brahmi, Mehdi, additional, Lo Vullo, Salvatore, additional, Cojocaru, Elena, additional, Mir, Olivier, additional, Casanova, Michela, additional, Vincenzi, Bruno, additional, De Pas, Tommaso Martino, additional, Grignani, Giovanni, additional, Pantaleo, Maria Abbondanza, additional, Blay, Jean Yves, additional, Jones, Robin Lewis, additional, Le Cesne, Axel, additional, Frezza, Anna Maria, additional, Gronchi, Alessandro, additional, Collini, Paola, additional, Dei Tos, Angelo Paolo, additional, Morosi, Carlo, additional, Mariani, Luigi, additional, Casali, Paolo Giovanni, additional, and Stacchiotti, Silvia, additional

Published
2020
Full Text
View/download PDF

25. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone – Multicenter analysis outside clinical trial

Author

Rutkowski, Piotr, Gaston, Louie, Borkowska, Aneta, Stacchiotti, Silvia, Gelderblom, Hans, Baldi, Giacomo Giulio, Palmerini, Emanuela, Casali, Paolo, Gronchi, Alessandro, Parry, Michael, Campanacci, Domenico Andrea, Scoccianti, Guido, Wagrodzki, Michal, Ferrari, Stefano, Dijkstra, Sander, Pieńkowski, Andrzej, and Grimer, Robert

Subjects
Denosumab, Giant cell tumor of bone, Neoadjuvant therapy, RANKL, Adolescent, Adult, Aged, Aged, 80 and over, Bone Density Conservation Agents, Bone Neoplasms, Disease-Free Survival, Dose-Response Relationship, Drug, Europe, Female, Giant Cell Tumor of Bone, Humans, Male, Middle Aged, Radiography, Retrospective Studies, Survival Rate, Treatment Outcome, Young Adult, Femur, Neoplasm Staging, Tibia, Surgery, Oncology
Published
2018

26. Activity of hormonal treatment in uterine smooth muscle tumors of uncertain malignant potential (STUMP): A mono-institutional referral center experience in advanced disease.

Author

Sanfilippo, Roberta, primary, Sbaraglia, Marta, additional, Fumagalli, Elena, additional, Baldi, Giacomo Giulio, additional, Fucà, Giovanni, additional, Morosi, Carlo, additional, Barisella, Marta, additional, Dei Tos, Angelo Paolo, additional, and Casali, Paolo Giovanni, additional

Published
2019
Full Text
View/download PDF

27. Activity of chemotherapy in inflammatory myofibroblastic tumor (IMT): A retrospective analysis within the Italian Rare Tumours Network (RTR).

Author

Baldi, Giacomo Giulio, primary, Gronchi, Alessandro, additional, Vincenzi, Bruno, additional, De Pas, Tommaso Martino, additional, Pantaleo, Maria A., additional, D'Ambrosio, Lorenzo, additional, Grignani, Giovanni, additional, Casanova, Michela, additional, Ferrari, Andrea, additional, Simeone, Noemi, additional, Provenzano, Salvatore, additional, Dei Tos, Angelo Paolo, additional, Sbaraglia, Marta, additional, Collini, Paola, additional, Dagrada, Gianpaolo, additional, Morosi, Carlo, additional, Casali, Paolo Giovanni, additional, and Stacchiotti, Silvia, additional

Published
2019
Full Text
View/download PDF

28. Activity of sirolimus in advanced epithelioid hemangioendothelioma (EHE): A retrospective analysis within the Italian Rare Tumor Network (RTR).

Author

Simeone, Noemi, primary, Baldi, Giacomo Giulio, additional, Frezza, Anna Maria, additional, Palassini, Elena, additional, David, Bruna Bianca Lopes, additional, Vincenzi, Bruno, additional, Brunello, Antonella, additional, Dagrada, Gianpaolo, additional, Collini, Paola, additional, Morosi, Carlo, additional, Dei Tos, Angelo Paolo, additional, Casali, Paolo Giovanni, additional, and Stacchiotti, Silvia, additional

Published
2019
Full Text
View/download PDF

29. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone – Multicenter analysis outside clinical trial

Author

Rutkowski, Piotr, primary, Gaston, Louie, additional, Borkowska, Aneta, additional, Stacchiotti, Silvia, additional, Gelderblom, Hans, additional, Baldi, Giacomo Giulio, additional, Palmerini, Emanuela, additional, Casali, Paolo, additional, Gronchi, Alessandro, additional, Parry, Michael, additional, Campanacci, Domenico Andrea, additional, Scoccianti, Guido, additional, Wagrodzki, Michal, additional, Ferrari, Stefano, additional, Dijkstra, Sander, additional, Pieńkowski, Andrzej, additional, and Grimer, Robert, additional

Published
2018
Full Text
View/download PDF

33. Case 2 – Lack of response to trastuzumab in a patient with metastatic gastric cancer progressing after extended response to MET inhibitor therapy

Author

Mori, Elena, Baldi, Giacomo Giulio, Scatizzi, Marco, Castagnoli, Antonio, Pugliese, Lavinia, Di Fiore, Giuseppe, Fargnoli, Rossana, Laera, Letizia, Di Donato, Samantha, Daniele, Bruno, Mori, Elena, Baldi, Giacomo Giulio, Scatizzi, Marco, Castagnoli, Antonio, Pugliese, Lavinia, Di Fiore, Giuseppe, Fargnoli, Rossana, Laera, Letizia, Di Donato, Samantha, and Daniele, Bruno

Abstract

In patients with advanced gastric cancer with high expression of HER2 protein, the addition of trastuzumab to chemotherapy significantly improves overall survival compared with chemotherapy alone in the first line setting. However, there are no data on anti-HER2 therapies beyond disease progression after first-line therapy. In many types of cancers, including gastric cancer, dysregulation of the receptor tyrosine kinase MET may lead to a more aggressive cancer phenotype and may be a negative prognostic indicator. Therapeutic targeting of MET/hepatocyte growth factor (HGF) signalling has used monoclonal antibodies and smallmolecule tyrosine kinase inhibitors (TKIs) against the MET receptor and its ligand, with several drugs in latephase clinical trials, including onartuzumab. Onartuzumab is a humanized monovalent monoclonal antibody directed against the hepatocyte growth factor receptor (c-Met). In advanced gastric cancer, the addition of onartuzumab to a standard chemotherapy regimen with oxaliplatin and fluoropyrimidine did not improve efficacy in gastric cancer patients in the overall study population or in those selected for positive MET status by immunohistochemistry. In this clinical case we observed a good clinical response to FOLFOX plus onartuzumab in a young patient with MET-positive gastric cancer. However, therapy with cisplatin, 5-fluorouracil and trastuzumab used after progression did not provide a benefit. This case report therefore highlights the importance of always fully identifying potential therapeutic targets in our patients in order to offer more personalized therapies. A correct molecular analysis is very important in deciding the therapeutic sequences in the metastatic setting.

Published
2016

34. Managing pazopanib toxicity in the treatment of advanced soft tissue sarcoma

Author

Boccone, Paola, Laera, Letizia, Baldi, Giacomo Giulio, Miano, Sara, Aliberti, Sandra, Tolomeo, Francesco, D’Ambrosio, Lorenzo, Grignani, Giovanni, Boccone, Paola, Laera, Letizia, Baldi, Giacomo Giulio, Miano, Sara, Aliberti, Sandra, Tolomeo, Francesco, D’Ambrosio, Lorenzo, and Grignani, Giovanni

Abstract

Background Pazopanib is a multikinase inhibitor registered for the treatment of advanced renal clear cell carcinoma (RCC) and as second or further-line therapy in advanced non-adipocytic soft tissue sarcoma (STS). It is a relatively well-tolerated compound, but, as with many other tyrosine kinase inhibitors (TKI), chronic toxicity may become a challenge that both patient and physician need to take into account when starting treatment. This retrospective study investigated toxicities and their management in STS patients treated with pazopanib in routine clinical practice in Italy. Materials and Methods Data were collected between January 2013 and May 2016 at Candiolo Cancer Institute and Prato Medical Oncology Unit. The primary objective was to describe observed toxicities in a real-life setting, and use this information to inform strategies for adverse event management. Results A total of 43 patients with advanced STS who received treatment with pazopanib were included. Median progression-free survival was 4 months and median overall survival was 18 months. The most common toxicities were fatigue (74.4%), hypertension (72%), hair hypopigmentation (74.4%) and diarrhea (60.5%). Liver toxicities occurred in less than one-third of patients. Severe adverse events, requiring drug interruption, were relatively rare. Conclusions This study confirms the safety and efficacy of pazopanib in pretreated unresectable or metastatic soft tissue sarcoma, and highlights the importance of close follow-up and patient support to improve compliance and treatment duration.

Published
2016

35. Use of first-line trabectedin in advanced leiomyosarcoma: a review of clinical data and future perspectives

Author

Hindi, Nadia, Duffaud, Florence, Baldi, Giacomo Giulio, Pautier, Patricia, Hindi, Nadia, Duffaud, Florence, Baldi, Giacomo Giulio, and Pautier, Patricia

Abstract

Leiomyosarcomas (LMS) represent a large subgroup of soft-tissue sarcoma (STS) generally considered moderately sensitive to conventional chemotherapy. Single-agent doxorubicin is the standard first-line therapy for advanced non-selected STS, although combination with ifosfamide appears to be superior in terms of objective response. Gemcitabine-based regimes, dacarbazine, trabectedin and pazopanib seem to be especially active in patients with advanced LMS, while the activity of ifosfamide in this histotype is low. Data derived from clinical trials and retrospective series show that trabectedin is especially active in L-sarcomas including non-gynecological and uterine LMS as well as liposarcomas, in particular myxoid liposarcomas. Trabectedin has also been tested in the first-line setting, alone or in combination with doxorubicin, for the treatment of LMS of uterine and non-uterine origin in a trial by the French Sarcoma Group (phase II study LMS-02) with encouraging results in terms of median progression-free survival and objective response. The toxicity profile of trabectedin appears to be comparable to, or even more manageable than, that of other chemotherapy combinations in the first-line setting. Designing new clinical trials based on specific histologic subtypes is feasible, and the results of such studies would help to optimize the management of patients with STS.

Published
2016

36. Guideline-Based Follow-Up Outcomes in Patients With Gastrointestinal Stromal Tumor With Low Risk of Recurrence: A Report From the Italian Sarcoma Group.

Author

D'Ambrosio, Lorenzo, Fumagalli, Elena, De Pas, Tommaso Martino, Nannini, Margherita, Bertuzzi, Alexia, Carpano, Silvia, Boglione, Antonella, Buonadonna, Angela, Comandini, Danila, Gasperoni, Silvia, Vincenzi, Bruno, Brunello, Antonella, Badalamenti, Giuseppe, Maccaroni, Elena, Baldi, Giacomo Giulio, Merlini, Alessandra, Mogavero, Andrea, Ligorio, Francesca, Pennacchioli, Elisabetta, and Conforti, Fabio

Published
2023
Full Text
View/download PDF

39. Trabectedin (T) versus adriamycin plus dacarbazine (A-DA) in advanced solitary fibrous tumor (SFT): Results from a phase II randomised clinical study (STRADA).

Author

Stacchiotti, Silvia, Grignani, Giovanni, Vincenzi, Bruno, Carreca, Ignazio, Palmerini, Emanuela, Collini, Paola, Dei Tos, Angelo Paolo, Dagrada, Gianpaolo, Zaffaroni, Nadia, Gronchi, Alessandro, Ignazzi, Gianluca, Appolloni, Viviana, Ingrosso, Matilde, Frezza, Anna Maria, Casali, Paolo Giovanni, Morosi, Carlo, Mariani, Luigi, and Baldi, Giacomo Giulio

Published
2023
Full Text
View/download PDF

40. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series

Author

Girolami, Ilaria, primary, Mancini, Irene, additional, Simoni, Antonella, additional, Baldi, Giacomo Giulio, additional, Simi, Lisa, additional, Campanacci, Domenico, additional, Beltrami, Giovanni, additional, Scoccianti, Guido, additional, D'Arienzo, Antonio, additional, Capanna, Rodolfo, additional, and Franchi, Alessandro, additional

Published
2015
Full Text
View/download PDF

41. Denosumab in patients with resectable giant cell tumor of bone (GCTB): Effect on surgical downstaging in a “real world” experience.

Author

Baldi, Giacomo Giulio, primary, Beltrami, Giovanni, additional, Scoccianti, Guido, additional, D'Arienzo, Antonio, additional, Campanacci, Domenico, additional, Frenos, Filippo, additional, Franchi, Alessandro, additional, Roselli, Giuliana, additional, Di Leo, Angelo, additional, and Capanna, Rodolfo, additional

Published
2015
Full Text
View/download PDF

42. Soft tissue sarcoma in Italy: From epidemiological data to clinical networking to improve patient care and outcomes

Author

Nora Drove, Giuseppe Badalamenti, Angelo Paolo Dei Tos, Emanuela Palmerini, Morena Caira, Andrea Marrari, Annalisa Trama, Giacomo Giulio Baldi, Bruno Vincenzi, Giovanni Grignani, Antonella Brunello, Trama, Annalisa, Badalamenti, Giuseppe, Baldi, Giacomo Giulio, Brunello, Antonella, Caira, Morena, Drove, Nora, Marrari, Andrea, Palmerini, Emanuela, Vincenzi, Bruno, Dei Tos, Angelo Paolo, Grignani, Giovanni, Trama A., Badalamenti G., Baldi G.G., Brunello A., Caira M., Drove N., Marrari A., Palmerini E., Vincenzi B., Dei Tos A.P., and Grignani G.

Subjects
Registrie, medicine.medical_specialty, Cancer Research, Histology, Epidemiology, Cancer registrie, Soft Tissue Neoplasms, Disease, European reference network, Patient care, Clinical expertise, 03 medical and health sciences, 0302 clinical medicine, medicine, Prevalence, Humans, Cancer registries, Registries, 030212 general & internal medicine, Stage (cooking), Intensive care medicine, Soft tissue sarcoma, Reference centres, business.industry, Incidence, Italian rare cancer network, Regional variability, Oncology, Reference centre, Cancer, Sarcoma, medicine.disease, Italy, 030220 oncology & carcinogenesis, Patient Care, business, Large group, Human
Abstract

Sarcomas are rare malignant neoplasms that develop from mesenchymal cells and include a heterogeneous and large group of histological subtypes that may occur at any anatomical site. Soft tissue sarcomas (STS), the focus of this review, account for ≈70‒80% of sarcomas and represent

Published
2019

43. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial

Author

Paolo G. Casali, Robert J. Grimer, P. D. Sander Dijkstra, Hans Gelderblom, Emanuela Palmerini, Andrzej Pieńkowski, Michal Wagrodzki, Domenico Andrea Campanacci, Stefano Ferrari, Louie Gaston, Piotr Rutkowski, Michael Parry, Alessandro Gronchi, Giacomo Giulio Baldi, Guido Scoccianti, Aneta Borkowska, Silvia Stacchiotti, Rutkowski, Piotr, Gaston, Louie, Borkowska, Aneta, Stacchiotti, Silvia, Gelderblom, Han, Baldi, Giacomo Giulio, Palmerini, Emanuela, Casali, Paolo, Gronchi, Alessandro, Parry, Michael, Campanacci, Domenico Andrea, Scoccianti, Guido, Wagrodzki, Michal, Ferrari, Stefano, Dijkstra, Sander, Pieńkowski, Andrzej, and Grimer, Robert

Subjects
0301 basic medicine, Male, medicine.medical_treatment, 0302 clinical medicine, Retrospective Studie, Femur, Neoadjuvant therapy, Aged, 80 and over, Bone Density Conservation Agents, RANKL, General Medicine, Middle Aged, Primary tumor, Curettage, Giant cell tumor of bone, Europe, Survival Rate, Denosumab, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Female, Giant-cell tumor of bone, medicine.drug, Human, Adult, medicine.medical_specialty, Bone Density Conservation Agent, Adolescent, Bone Neoplasms, Bone Neoplasm, Disease-Free Survival, 03 medical and health sciences, Young Adult, medicine, Humans, Survival rate, Retrospective Studies, Aged, Neoplasm Staging, Dose-Response Relationship, Drug, Tibia, business.industry, medicine.disease, Surgery, Radiation therapy, Radiography, 030104 developmental biology, Osteonecrosis of the jaw, business
Abstract

Background Giant cell tumor of bone (GCTB) is an osteolytic, locally aggressive, rarely metastazing bone tumor. This is a retrospective study evaluating a large series of GCTB patients treated with denosumab in routine practice in 6 European reference centers. Methods Patients with locally advanced, unresectable or metastatic GCTB, treated with denosumab outside clinical trials were eligible. Primary end-point was progression-free survival (PFS) for all patients; secondary end-points were: type of surgery, relapse rate and event-free survival for patients after preoperative denosumab + surgery. Results We identified 138 patients treated in the period 2011–2016. In 40/43 cases the diagnosis was confirmed by H3F3A gene mutation. Median follow-up time was 23 months (range 6–48). Primary tumor was located in lower limb (38%) - mostly in femur and tibia, in upper limb (34%), and in pelvis/axial skeleton/ribs (28%). 110 (80%) patients had primary tumors, 28 (22%) recurrent tumors after previous surgical procedures (+/− radiotherapy). 89/138 patients had locally advanced GCTB and underwent neoadjuvant denosumab. The median denosumab treatment duration was 8 months (median number of cycles 11), 98% had clinical benefit from therapy. 39 (44%) had wide en-bloc resection - WE (+implantation of the prosthesis in 17 cases), the other 50 (56%) cases had intralesional curettage - C. Progression after surgical treatment was observed in 19 patients, 16 of them after C (32%); 13 patients underwent denosumab re-challenge, and all responded. Two-year progression-free survival (PFS; from denosumab start) rate was 81%; 2-year EventFS (from surgery) was significantly better in WE group (93%) vs 55% in C group (p = 0.006). Treatment was well tolerated with only 2 cases of grade 3 toxicity and one osteonecrosis of the jaw. Conclusion Our retrospective study confirms that denosumab is extremely efficient in unresectable/metastatic disease as well as in a neoadjuvant setting. Our data confirm excellent efficacy and short-term tolerability of this drug. Our data suggest that neoadjuvant therapy with denosumab is the option for treatment of initially locally advanced tumors to facilitate complete surgical resection or avoid mutilating surgery. The risk of recurrences after curettage of GCTB following denosumab raises questions about the optimal management of such cases.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results